Breaking News
November 22, 2018 - Response to daily stressors plays important role in cognitive health of older adults
November 22, 2018 - Efficient method for producing induced pluripotent stem cells
November 22, 2018 - Report outlines inequalities in access to healthcare
November 22, 2018 - New research center will pave way to better diagnosis and treatment of skin diseases
November 22, 2018 - Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
November 22, 2018 - Lung Cancer Tumor Markers: MedlinePlus Lab Test Information
November 22, 2018 - Patchy distribution of joint inflammation resolved
November 22, 2018 - Researchers find crucial inhibitory role for signal peptide in GluK1 trafficking
November 22, 2018 - nutritional supplement, could slow some cancers
November 22, 2018 - Researchers awarded $7 million funding in Pancreatic Cancer Collective’s ‘New Therapies Challenge’
November 22, 2018 - UMN researchers focus on improving dermatologic care for sexual and gender minority patients
November 22, 2018 - Researchers harness visible light to develop safer building block for drug discovery
November 22, 2018 - Scientists identify key protein involved in Hantavirus Pulmonary Syndrome
November 22, 2018 - ACAAI: Oral Immunotherapy Is Protective in Peanut Allergy
November 22, 2018 - Arthritis and depression often occur together in older adults
November 22, 2018 - Scientists uncover unexpected ‘foreign’ genes in tiny itch-inducing chigger mite
November 22, 2018 - Negative social cues on tobacco packaging could help reduce smoking intentions
November 22, 2018 - Study finds no differences in quit rates for ‘dual users’ of both traditional and electronic cigarettes
November 22, 2018 - Immunity connects gut microbiota and age-related pathologies
November 22, 2018 - New diagnostics based on nanopore analytics and AI can identify single influenza virions
November 22, 2018 - Blocking activity of plasma protein can be possible way to protect against radiation-induced injury
November 22, 2018 - Secondhand Pot Smoke Found in Kids’ Lungs
November 22, 2018 - Air pollution may be linked to heightened dementia risk
November 22, 2018 - Brain implant lets people with limb paralysis compose and send emails, select videos and even play music, just by thinking
November 22, 2018 - Should health-care workers press charges against violent patients?
November 22, 2018 - Obesity linked to COPD in never-smokers
November 22, 2018 - Improving dementia treatment and staff training in care homes saves thousands of pounds per year
November 22, 2018 - Researchers identify genetic changes that could increase risk for death by suicide
November 22, 2018 - John Snow Labs launches new Data Market to help healthcare and life science innovators
November 22, 2018 - New inhibitor could hold key to treating Acute Respiratory Distress Syndrome
November 22, 2018 - Misconceptions about opioid use undermine pain control among Asian cancer patients
November 22, 2018 - Owlstone Medical named Medtech Company of the Year
November 22, 2018 - Anabolic steroids may increase risk of early death in men
November 22, 2018 - Researchers develop model that predicts transmissibility of viral zoonoses
November 22, 2018 - Evidence mounts that an eye scan may detect early Alzheimer’s disease
November 22, 2018 - Sensors could provide dexterity to robots, with potential surgical applications
November 22, 2018 - Why Are We Still So Fat?
November 22, 2018 - MRI scans may help predict dementia risk
November 22, 2018 - Groundbreaking research projects show how AI can be used to predict under diagnosed chronic diseases
November 21, 2018 - Stand Up to Cancer supports potential approach to more efficiently target pancreatic cancer
November 21, 2018 - Using smartphone confocal microscopes to stop cancer
November 21, 2018 - Self-care program for COPD patients reduces emergency room visits and burdensome symptoms
November 21, 2018 - Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
November 21, 2018 - Cocaine adulterant may cause brain damage
November 21, 2018 - Amid the devastation, a Stanford doctor stitches up George, a search dog
November 21, 2018 - America’s Health-Care System Is Making the Opioid Crisis Worse
November 21, 2018 - Colorectal cancer screening reduces need for intense treatments among male patients
November 21, 2018 - Scientists find evidence of prions in the eyes of CJD patients
November 21, 2018 - Study explores individual and organizational risk factors for one-year mortality in ICU survivors
November 21, 2018 - Pulmonologists want more information on inhalation devices for COPD
November 21, 2018 - Cessation fatigue predicts relapse rate after attempts to quit smoking
November 21, 2018 - Special care should be taken with drugs that inhibit epigenetic factors, study suggests
November 21, 2018 - More than one in ten heavy cannabis users experience withdrawal after quitting cannabis
November 21, 2018 - Reflections on the California fires
November 21, 2018 - Donna Lynne Appointed to Key Leadership Role at CUIMC
November 21, 2018 - Smoke-free laws associated with reduced systolic blood pressure
November 21, 2018 - Achieving new guideline blood pressure goals may prevent 3 million cardiovascular events
November 21, 2018 - LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data
November 21, 2018 - Older adults with CVD more likely to experience rapid functional decline
November 21, 2018 - Purified omega-3 and aspirin reduce pre-cancerous bowel polyps, shows study
November 21, 2018 - Study warns that potential epigenetic therapy may boost lung cancer stem cells
November 21, 2018 - Noise pollution in hospital impact quality and safety of healthcare
November 21, 2018 - Interventions to improve sleep may reduce risk of falls
November 21, 2018 - Outdoor air pollution linked to intellectual disabilities in children
November 21, 2018 - Study highlights need for better screening tools to detect maternal sepsis
November 21, 2018 - Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM
November 21, 2018 - Researchers stop ‘sneaky’ cancer cells in their tracks
November 21, 2018 - People who are afraid to draw their blood over-estimate the risk of fainting
November 21, 2018 - Personalized physical exercise reverses functional, cognitive deterioration in the elderly
November 21, 2018 - COPD linked to obesity in older women who have never smoked
November 21, 2018 - AHA: Cold-Weather Drinks Are Here, But Watch Out for the Calories
November 21, 2018 - Crowds line up at 1st East Coast pot shops
November 21, 2018 - Merck declares 2018 Life Science Award winners
November 21, 2018 - Many people underestimate the impact of sprains, say foot scientists
November 21, 2018 - Lower levels of protein make squamous carcinoma cells more invasive
November 21, 2018 - Study highlights a new predictor of type 2 diabetes
November 21, 2018 - NTU and TTSH join forces to improve doctor-patient communication
November 21, 2018 - New low-cost injectable hydrogel could help wounds heal faster
November 21, 2018 - Merck Announces Winners of 2018 Life Science Awards
November 21, 2018 - Check your medical records for dangerous errors
FDA and DOD sign MOU regarding medical product development and assessment

FDA and DOD sign MOU regarding medical product development and assessment

image_pdfDownload PDFimage_print

Today, the U.S. Food and Drug Administration and the Department of Defense’s (DoD) Office of Health Affairs signed a Memorandum of Understanding regarding medical product development and assessment. This builds upon the work of both agencies to foster and prioritize the efficient development of safe and effective medical products intended to save the lives of American service members.

“We’re extremely grateful to the men and women who defend our nation, often at great personal risk and sacrifice. It’s our honor and duty to support our military personnel by ensuring they have access to safe and effective medical products – especially products that meet the unique needs and settings in which soldiers may require medical treatment,” said FDA Commissioner Scott Gottlieb, M.D. “The FDA has already been working closely with the DoD to identify opportunities to expedite availability of medical products, particularly those products used to treat injuries in battlefield settings. For example, as noted below, the Emergency Use Authorization for French freeze-dried plasma that was issued earlier this year. Our close collaboration with DoD has helped us target and more efficiently address DoD’s immediate product priorities and foster development and review of these products in the most streamlined manner possible. We are looking forward to additional partnership opportunities under the MOU.”

The MOU formally establishes the framework under which the DoD and the FDA will implement the law passed by Congress in 2017 for enhanced engagements between the DoD and the FDA. Under the terms of this MOU, the FDA will work closely with the DoD to evaluate how best to foster access to safe and effective medical products that serve the military’s medical needs; give the highest level of attention to and expedite review of priority DoD medical products; provide ongoing technical advice to aid in the rapid development and manufacturing of medical products for use by the military; and examine products currently under development to determine opportunities to streamline review and expedite their availability. The 2017 law also expanded the FDA’s authority to authorize emergency uses of medical products to reduce deaths and severity of injuries caused by chemical, biological, radiological or nuclear (CBRN) agents or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to the U.S. military forces and for other purposes.

“This MOU furthers the existing partnership between the Department of Defense and the FDA to equip our military with the best and most innovative military medical support possible,” said Terry M. Rauch, Ph.D., M.P.H., M.B.A., Acting Deputy Assistant Secretary of Defense, Health Readiness Policy & Oversight, DOD. “Our servicemen and women risk their lives protecting our country. Today’s MOU reflects the commitment of the DoD and the FDA to ensure timely access to life-saving medical products for U.S. troops and to continue fostering the development of new innovative medical products that can help ensure the operational readiness of American troops. We look forward to continuing to work with the FDA as we analyze and implement measures to provide the best possible medical products and care to all military personnel – on the battlefield, stationed around the world and at home.”

“Our enhanced collaboration with our DoD partners has been vital to gaining a better understanding of the health needs of those protecting our country,” said Anna Abram, the FDA’s Deputy Commissioner for Policy, Planning, Legislation and Analysis. “Today’s MOU is a key milestone in implementing a robust and enduring pathway that fulfills our commitment to expedite access to safe and effective medical products for our military personnel.”

The MOU signed today builds upon the approach that the FDA outlined in 2018 to advance the development and availability of medical products to help save the lives of American military personnel in a work plan developed in close collaboration with the DoD. The MOU reflects the agency’s commitment to working to address the medical needs of military personnel, especially by helping to expedite the development and review of medical products that are a priority for the DoD and to aid in the rapid development and manufacturing of safe and effective medical products for use by the U.S. military. Specifically, the MOU sets forth a framework to implement the 2017 law, which included provisions to allow the Secretary of Defense to request, and the FDA to take, specific actions to expedite the development of medical products, and the review of investigational submissions, applications for approval/licensure, and submissions/notifications for clearance for such medical products to diagnose, prevent, treat or mitigate a specific and life-threatening risk to the U.S.

As part of the ongoing and frequent collaborations between the FDA and the DoD, additional steps taken over the past several months include:

  • In July 2018, the FDA granted an Emergency Use Authorization (EUA) for the DoD’s emergency use of Pathogen-Reduced Leukocyte-Depleted Freeze-Dried Plasma manufactured by the Centre de Transfusion Sanguine des Armées (often referred to as French freeze-dried Plasma). That action reflected the importance that both the DoD and the FDA place on efficiently prioritizing and expediting availability of potentially life-saving biological products that are essential to the urgent care of military personnel, especially those in potential battlefield settings. Granting this authorization supported access to this important product and ensures that it will be available if needed.
  • In July 2018, the FDA approved the atropine autoinjector device as a medical countermeasure for chemical nerve agent exposure. This drug-device product was developed in partnership with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, and was approved six months ahead of the DoD’s product development schedule.
  • In August 2018, following a priority review, the FDA approved the first prophylactic drug for malaria in over 18 years, tafenoquine (Arakoda). This drug was developed in partnership with the U.S. Army Medical Research and Materiel Command.
  • On October 29, 2018, the FDA issued draft guidance to help foster the development and eventual approval of dried plasma products. Since these types of plasma products do not need to be stored frozen and can be reconstituted and administered quickly they can be used by military personnel in remote areas without freezers and other support equipment.

The FDA and the DoD are committed to the ongoing partnership and are confident that today’s MOU will enhance those efforts to better serve the health care needs of American military personnel.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624970.htm

Tagged with:

About author

Related Articles